NEW YORK (GenomeWeb News) – Microfluidic systems developer Fluxion Biosciences has received a Phase I grant from the National Institutes of Health to develop a platform for use in antimicrobial drug discovery and development programs, the company said today.
 
The San Francisco-based company did not disclose the amount of the grant and was not immediately available for comment.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.